stockrow
Monday 9 November 2026
Export GLSI’s income statement to Excel — free account
Greenwich LifeSciences, Inc.
GLSI- EPS
- +3.57%
- Free cash flow
- +13.1%
Quarter to June 2026, against a year earlier
15.17
0.52
+3.55%
Follow GLSI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | (2) | (2) | (3) | (2) | (5) | (8) | (9) | (17) | (19) | (22) | +36.9% | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (2) | (3) | (2) | (5) | (8) | (9) | (17) | (19) | (22) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | (0.13) | (0.14) | (1.52) | (0.20) | (0.35) | (0.61) | (0.69) | (1.34) | (1.43) | (1.51) | +35.0% | ||||||
| Cash flow | — | (0.01) | (0.01) | (0.13) | (0.12) | (0.33) | (0.48) | (0.50) | (0.56) | (0.73) | (0.85) | +70.4% | ||||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | (0.01) | (0.01) | (0.13) | (0.12) | (0.33) | (0.48) | (0.50) | (0.56) | (0.73) | (0.85) | +70.4% | ||||||
| Book value | — | (0.73) | (0.86) | (0.60) | 2.91 | 2.07 | 1.02 | 0.52 | 0.07 | 0.03 | 0.21 | n/m | ||||||
| Shares, m | — | 12 | 12 | 2 | 9 | 13 | 13 | 13 | 13 | 14 | 14 | +1.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | 0 | 0 | (1) | (4) | (6) | (6) | (7) | (10) | (12) | +73.5% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | 0 | 0 | 0 | (1) | (4) | (6) | (6) | (7) | (10) | (12) | +73.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | (1) | (1) | (1) | 28 | 27 | 13 | 7 | 1 | 0 | 3 | n/m | |||||
| Net debt | — | 0 | 0 | 0 | (29) | (27) | (13) | (7) | (4) | (6) | (9) | +297.1% | ||||||
| Shareholders’ equity | — | (9) | (10) | (1) | 28 | 27 | 13 | 7 | 1 | 0 | 3 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (2,320.80) | (3,114.65) | (5,067.01) | (12.98) | (16.35) | (38.46) | (86.87) | (314.09) | (376.92) | (374.46) | +1,943.9 pt | |||||
| ROIC | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | 16.86 | 18.11 | 59.69 | (14.18) | (16.78) | (39.08) | (89.30) | (457.73) | (3,068.35) | (986.31) | (3,085.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 3 | 3 | 6 | 6 | 7 | 8 | 13 | — | +27.7% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Greenwich LifeSciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio, Inc. | $280.4M | — (loss-making) | — | — | n/m | −35.72% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ABEO Abeona Therapeutics Inc. | $238.5M | — (loss-making) | — (loss-making) | +225.14% (above 0%: growing) | n/m | +17.11% (above 0%: growing) | 63.30% | (119.97%) | Compare |
| IMRX Immuneering Corporation | $238.3M | — (loss-making) | — (loss-making) | −99.74% (below 0%: shrinking) | n/m | −40.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VNDA Vanda Pharmaceuticals Inc. | $231.0M | — (loss-making) | — (loss-making) | +24.10% (above 0%: growing) | n/m | +9.57% (above 0%: growing) | 94.05% | (33.69%) | Compare |
| ACIU AC Immune | $227.0M | — (loss-making) | — (loss-making) | +152.31% (above 0%: growing) | n/m | +4.66% (above 0%: growing) | 100.00% | (302.13%) | Compare |
| FATE Fate Therapeutics, Inc. | $223.1M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| GLSI Greenwich LifeSciences, Inc. | $222.7M | — (loss-making) | — | — | n/m | +13.14% (above 0%: growing) | 0.00% | 0.00% | |
| KRRO Korro Bio, Inc. | $202.5M | — (loss-making) | — (loss-making) | −86.28% (below 0%: shrinking) | n/m | +12.07% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SLGL Sol-Gel Technologies Ltd. | $199.8M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| Median of peers | $229.0M | — | — | +9.18% | — | +6.81% | 97.03% | (76.83%) |
Pay and ownership Proxy statement filed 3 November 2025
Ownership
Directors and executive officers, together
51.47%
Snehal Patel
41.11%
David McWilliams
5.08%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement